Feedback
Settings

Settings

Goto Application

1. WO2022045247 - ANTI-TRUNCATED MUTANT CALR-CD3 BISPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION

Submit observation
PermaLink
Publication Number WO/2022/045247
Publication Date 03.03.2022
International Application No. PCT/JP2021/031355
International Filing Date 26.08.2021
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07K 16/18 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/46 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61K 51/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Applicants
  • 学校法人順天堂 JUNTENDO EDUCATIONAL FOUNDATION [JP]/[JP]
  • Ｍｅｉｊｉ　Ｓｅｉｋａファルマ株式会社 MEIJI SEIKA PHARMA CO., LTD. [JP]/[JP]
Inventors
  • 小松　則夫 KOMATSU, Norio
  • 荒木　真理人 ARAKI, Marito
  • 木原　慶彦 KIHARA, Yoshihiko
  • 石田　陽治 ISHIDA, Yoji
  • 北村　弘一 KITAMURA, Koichi
  • 福島　崇恵 FUKUSHIMA, Takayoshi
  • 安井　佳織 YASUI, Kaori
Agents
  • 特許業務法人アルガ特許事務所 THE PATENT CORPORATE BODY ARUGA PATENT OFFICE
Priority Data
2020-14355127.08.2020JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) ANTI-TRUNCATED MUTANT CALR-CD3 BISPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION
(FR) ANTICORPS BISPÉCIFIQUE CALR-CD3 MUTANT ANTI-TRONQUÉ ET COMPOSITION PHARMACEUTIQUE
(JA) 抗切断型変異ＣＡＬＲ－ＣＤ３二重特異性抗体及び医薬組成物
Abstract
(EN) Provided are: a higher-performance bispecific antibody that specifically binds to a mutant calreticulin protein; and a pharmaceutical composition that contains said antibody.　Provided is a bispecific antibody having: a first domain that specifically binds to a mutant calreticulin protein; and a second domain that specifically binds to a CD3 antigen.
(FR) L'invention concerne : un anticorps bispécifique à performance supérieure qui se lie spécifiquement à une protéine de calréticuline mutante; et une composition pharmaceutique qui contient ledit anticorps.　L'invention concerne un anticorps bispécifique ayant : un premier domaine qui se lie spécifiquement à une protéine de calréticuline mutante; et un second domaine qui se lie spécifiquement à un antigène CD3.
(JA) 変異型カルレティキュリンタンパク質に特異的に結合する、より高性能な二重特異性及び当該抗体を含有する医薬組成物を提供すること。　変異型カルレティキュリンタンパク質に特異的に結合する第１のドメイン及びＣＤ３抗原に特異的に結合する第２のドメインを有する二重特異性抗体を提供する。
Latest bibliographic data on file with the International Bureau
# -